Mostrando 2 resultados de: 2
The Cost-Effectiveness of Bendamustine-Rituximab Versus Fludarabine-Rituximab for Patients with Indolent Non-Hodgkin’s Lymphoma (INHL) Who Have Progressed Following Treatment …
OtherAbstract: Objectives To determine the cost-effectiveness of bendamustine-rituximab (Ben-R) versus fludarabine-Palabras claves:Autores:CARMEN BAYAS ZAMBRANOFuentes:googleThe cost-effectiveness of bendamustine-rituximab (BEN-R) versus R-CHOP for the first line treatment of patients with indolent non-Hodgkin’s lymphoma (INHL) in Colombia
OtherAbstract: Objectives To determine the cost-effectiveness of Ben-R versus R-CHOP for the first-line treatment oPalabras claves:Autores:CARMEN BAYAS ZAMBRANOFuentes:google